Health
Heterologous AstraZeneca and Pfizer vaccines induce strong immune response and T cell reactivity against multiple SARS-CoV-2 variants – News-Medical.Net
Researchers from Germany recently analyzed a cohort of 26 individuals in the age range of 25 to 46 (median 30.5) years who had received a ChAdOx1 nCoV-19 prime…
The first person to receive a coronavirus disease 2019 (COVID-19) vaccine outside a clinical trial did so within 250 days of the first case of COVID-19 being reported to the World Health Organization (WHO) in late 2019. Mass vaccination efforts are now a key strategy for controlling the pandemic. Several vaccines have been approved, including the mRNA-based BNT162b2 (Comirnaty, BioNTech/Pfizer) and the adenovirus-based ChAdOx1 nCoV-19 (Vaxzevria, AstraZeneca).
Both these vaccines induce humoral…
Continue Reading
